Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbiota Transplant Therapy for PAH
NCT04884971Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation capsules in pulmonary arterial hypertension (PAH), sponsored by University of Minnesota. Primary endpoints: Frequency of Serious Adverse Events at 6 months and Proportion of IMT Compliance at 6 months. Started Nov 2021; status: completed.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04884971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884971.